Wang Weili, Guan Songlei, Sun Shilong, Jin Yonglong, Lee Kuang-Hui, Chen Yubing, Wei Jun
Department of Radiobiology, School of Public Health, Jilin University, Changchun, 130021, China.
Tumour Biol. 2014 May;35(5):4901-5. doi: 10.1007/s13277-014-1643-4. Epub 2014 Jan 23.
The EarlyCDT®-Lung test was the first autoantibody-based diagnostic tool for lung cancer, which was developed with a panel of recombinant protein antigens. To confirm whether the antibody test developed with linear peptide antigens has a similar power to that developed with the whole protein molecules, the present work was then undertaken to develop an in-house enzyme-linked immunosorbent assay with linear peptide antigens derived from annexin A1 (ANXA1) and DEAD box protein 53 (DDX53), which have been used to develop the EarlyCDT®-Lung test. A total of 272 patients with non-small cell lung cancer (NSCLC) and 227 control subjects matched in age and smoking history were recruited. Student's t test showed that the levels of circulating IgG to ANXA1-derived peptide antigens were significantly higher in patients with NSCLC than control subjects (t = 5.66, P < 0.0001), in which the increased anti-ANXA1 IgG levels were observed only in patients at stages I, II, or III, but not in those at stage IV. However, the levels of circulating IgG to DDX53-derived peptide antigens were not significantly altered in NSCLC (t = 1.78, P = 0.076). Receiver operating characteristic analysis showed that the sensitivity against specificity of >90% was 23.7% for ANXA1 IgG assay and 13.8% for DDX53 IgG assay. This work suggests that the linear peptide antigen derived from ANXA1 may be suitable for the development of diagnostic tool for lung cancer although further screening is needed to identify more such peptide antigens derived from tumor-associated antigens.
EarlyCDT®-Lung检测是首个基于自身抗体的肺癌诊断工具，它是利用一组重组蛋白抗原开发而成的。为了确认用线性肽抗原开发的抗体检测是否具有与用完整蛋白分子开发的检测相似的效能，于是开展了本研究，以开发一种内部酶联免疫吸附测定法，该方法使用源自膜联蛋白A1（ANXA1）和DEAD盒蛋白53（DDX53）的线性肽抗原，这两种抗原已被用于开发EarlyCDT®-Lung检测。共招募了272例非小细胞肺癌（NSCLC）患者和227例年龄及吸烟史相匹配的对照受试者。学生t检验显示，NSCLC患者中针对ANXA1衍生肽抗原的循环IgG水平显著高于对照受试者（t = 5.66，P < 0.0001），其中仅在I、II或III期患者中观察到抗ANXA1 IgG水平升高，而IV期患者未观察到。然而，NSCLC患者中针对DDX53衍生肽抗原的循环IgG水平无显著变化（t = 1.78，P = 0.076）。受试者工作特征分析表明，ANXA1 IgG检测的灵敏度对特异性>90%为23.7%，DDX53 IgG检测为13.8%。这项研究表明，源自ANXA1的线性肽抗原可能适合用于开发肺癌诊断工具，尽管需要进一步筛选以鉴定更多源自肿瘤相关抗原的此类肽抗原。
